Mawer Investment Management Ltd. Raises Stake in Hologic, Inc. (NASDAQ:HOLX)

Mawer Investment Management Ltd. boosted its position in Hologic, Inc. (NASDAQ:HOLX) by 7.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 466,180 shares of the medical equipment provider’s stock after buying an additional 33,700 shares during the period. Mawer Investment Management Ltd. owned approximately 0.17% of Hologic worth $22,386,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. McGuire Investment Group LLC raised its stake in shares of Hologic by 20.6% during the 2nd quarter. McGuire Investment Group LLC now owns 96,190 shares of the medical equipment provider’s stock worth $4,619,000 after buying an additional 16,446 shares during the period. Fox Run Management L.L.C. acquired a new position in shares of Hologic during the 2nd quarter worth approximately $576,000. Stephens Investment Management Group LLC raised its stake in shares of Hologic by 0.6% during the 1st quarter. Stephens Investment Management Group LLC now owns 693,183 shares of the medical equipment provider’s stock worth $33,550,000 after buying an additional 4,176 shares during the period. Toronto Dominion Bank raised its stake in shares of Hologic by 17.5% during the 1st quarter. Toronto Dominion Bank now owns 192,929 shares of the medical equipment provider’s stock worth $9,336,000 after buying an additional 28,706 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Hologic by 5.3% during the 4th quarter. Geode Capital Management LLC now owns 3,805,329 shares of the medical equipment provider’s stock worth $156,146,000 after buying an additional 190,788 shares during the period. Hedge funds and other institutional investors own 96.17% of the company’s stock.

In related news, insider Peter J. Valenti III sold 4,545 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $44.07, for a total value of $200,298.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Stephen P. Macmillan sold 194,396 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $48.77, for a total value of $9,480,692.92. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.



NASDAQ HOLX traded down $1.71 during mid-day trading on Friday, hitting $48.13. The stock had a trading volume of 1,523,586 shares, compared to its average volume of 1,557,178. The firm’s 50 day moving average is $49.19 and its 200 day moving average is $47.07. Hologic, Inc. has a twelve month low of $37.47 and a twelve month high of $52.19. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.57 and a quick ratio of 1.11. The stock has a market capitalization of $13.46 billion, a price-to-earnings ratio of 21.58, a PEG ratio of 2.29 and a beta of 0.74.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $0.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.02. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The firm had revenue of $852.40 million during the quarter, compared to the consensus estimate of $836.91 million. During the same period in the prior year, the company earned $0.58 EPS. The firm’s revenue was up 3.4% compared to the same quarter last year. As a group, equities research analysts expect that Hologic, Inc. will post 2.44 earnings per share for the current year.

Several research analysts have recently weighed in on the company. TheStreet raised Hologic from a “c+” rating to a “b” rating in a research note on Wednesday, July 31st. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a research note on Saturday, July 27th. Argus upped their target price on Hologic to $62.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Canaccord Genuity reaffirmed a “hold” rating and set a $52.00 target price on shares of Hologic in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. Hologic currently has an average rating of “Hold” and a consensus target price of $48.94.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Technical Analysis

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.